Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Protalix BioTherapeutics, Inc.

Get SEC filing alerts via email and in your feed for Protalix BioTherapeutics, Inc.

PLX

Protalix BioTherapeutics, Inc.

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics is a biopharmaceutical company specializing in developing, manufacturing, and commercializing recombinant therapeutic proteins using its proprietary plant cell-based ProCellEx platform. Its core products include enzyme replacement therapies for rare diseases like Fabry and Gaucher. The company focuses on innovative treatments for high unmet medical needs, leveraging unique plant-based production methods to enhance safety, efficacy, and manufacturing flexibility.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Protalix BioTherapeutics, Inc.

1
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports $33.8 Million Revenue and $18.3 Million Net Income in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports $52.7 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports 24% Revenue Growth to $43.6 Million for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports 49% Revenue Growth and Improved Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports 170% Revenue Growth to $10.1 Million in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports 31% Revenue Growth to $53M for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports 36% Revenue Decline, Improved Operating Loss in Nine Months Ending September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments